Literature DB >> 28323111

Nanoparticles for tumor immunotherapy.

Xinlong Zang1, Xiuli Zhao1, Haiyang Hu1, Mingxi Qiao1, Yihui Deng2, Dawei Chen3.   

Abstract

Although most researches and therapies have been focused on the tumor itself, it is becoming clear that immune cells can not only suppress tumor development but support and maintain their malignant type. Promising recent developments in immunology will provide opportunities for tumor-specific immunotherapy, which can orchestrate the patients immune system to target, fight and eradicate cancer cells without destroying healthy cells. However, antitumor immunity driven by self-immune system alone may be therapeutically insufficient. Developments in nanoparticle based drug delivery system can promote immunotherapy and re-educate immunosuppressive tumor microenvironment (TME), which provide promising strategies for cancer therapy. In this review, we will focus on nanoparticle-based immunotherapeutic approaches against cancer, ranging from nanovaccines, artificial antigen presenting cells (aAPCs) to nanoparticles reversing tumor immunosuppressive microenvironment.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antitumor immune response; Artificial antigen presenting cells; Immunosuppression; Nanoparticles; Nanovaccines; Targeting to immunosuppressive cells; Tumor immunotherapy

Mesh:

Year:  2017        PMID: 28323111     DOI: 10.1016/j.ejpb.2017.03.013

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  21 in total

Review 1.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

2.  Fabrication of methylene blue-loaded ovalbumin/polypyrrole nanoparticles for enhanced phototherapy-triggered antitumour immune activation.

Authors:  Xiao Xu; Huafen Mao; Yunchao Wu; Suwan Liu; Jingjin Liu; Qianzhe Li; Mengyu Yang; Jinqian Zhu; Shengqiang Zou; Fengyi Du
Journal:  J Nanobiotechnology       Date:  2022-06-22       Impact factor: 9.429

3.  In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy.

Authors:  Xu-Dong Tang; Kui-Lin Lü; Jin Yu; Han-Jian Du; Chao-Qiang Fan; Lei Chen
Journal:  Cancer Immunol Immunother       Date:  2022-05-12       Impact factor: 6.630

4.  Unimicellar hyperstars as multi-antigen cancer nanovaccines displaying clustered epitopes of immunostimulating peptides.

Authors:  Hamilton Kakwere; Elizabeth S Ingham; Riley Allen; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Matthew T Silvestrini; Jamal S Lewis; Katherine W Ferrara
Journal:  Biomater Sci       Date:  2018-09-19       Impact factor: 6.843

Review 5.  Recent progress in nanomedicine for enhanced cancer chemotherapy.

Authors:  Guoqing Wei; Yu Wang; Guang Yang; Yi Wang; Rong Ju
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

Review 6.  Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease.

Authors:  Dhruv R Seshadri; Anand Ramamurthi
Journal:  Front Pharmacol       Date:  2018-07-16       Impact factor: 5.810

Review 7.  Bioactive Nanoparticles for Cancer Immunotherapy.

Authors:  Suchithra Poilil Surendran; Myeong Ju Moon; Rayoung Park; Yong Yeon Jeong
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

Review 8.  Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.

Authors:  Julia Koerner; Dennis Horvath; Marcus Groettrup
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 9.  Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.

Authors:  Christine E Boone; Lu Wang; Aayushma Gautam; Isabel G Newton; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-07-22

Review 10.  Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy.

Authors:  Jiawei Tu; Hui Zhang; Jinsui Yu; Chun Liufu; Zhiyi Chen
Journal:  Onco Targets Ther       Date:  2018-09-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.